iBio, Inc. received notice from the New York Stock Exchange that the Company fell below certain of the exchange’s continued listing standards. The Newark-based company is not in compliance with the requirement of a listed company having stockholders’ equity of less than $6 million.
In a release, iBio said it believes it can provide a compliance plan by Dec. 21st. If not, the company would be delisted from the exchange.
The Newark company develops vaccine systems that use plant technologies, robotics and other means. The approach reduces the costs and the amount of time required to manufacture vaccines. The company has struggled with a falling stock price, due to investor concerns about its earnings potential.